Literature DB >> 12069496

Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

Matthew F Kalady1, Mark W Onaitis, Karen M Padilla, Sirisha Emani, Douglas S Tyler, Scott K Pruitt.   

Abstract

BACKGROUND: Dendritic cells pulsed with mRNA provide a unique approach to tumor immunotherapy. We hypothesized that increased mRNA transfection efficiency and dendritic cell maturation would improve antigen processing and presentation as well as T-cell costimulation, resulting in enhanced induction of antimelanoma immune responses.
METHODS: Immature monocyte-derived dendritic cells were transfected with mRNA by passive pulsing, lipofection, or electroporation. Dendritic cells were either left untreated or matured using the double-stranded RNA poly(I:C). T-Cell cultures were generated by stimulation of naïve T-cells with each set of dendritic cells. Specific antigen presentation and specific effector T-cell generation were analyzed by an IFN-gamma release Elispot assay.
RESULTS: Greatest intracellular green fluorescent protein was observed by flow cytometry following dendritic cell electroporation with green fluorescent protein mRNA. DC presentation of Mart-1/Melan A peptide, as measured by Elispot assay using a specific T-cell clone, was greatest following transfection with Mart-1/Melan A mRNA by electroporation. Maturation of dendritic cells further improved antigen presentation regardless of transfection technique. Specific Mart-1/Melan A effector T cells were produced after culture of naïve T cells with dendritic cells that were electroporated with Mart-1/Melan A mRNA and then matured, but not for dendritic cells that remained immature.
CONCLUSIONS: Efficient mRNA transfection by electroporation as well as dendritic cell maturation results in increased levels of Mart-1/Melan A antigen presentation and enhanced production of antigen-specific effector T cells. This combination of strategies may be used to enhance immune responses to RNA-based dendritic cell vaccines. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069496     DOI: 10.1006/jsre.2002.6435

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  11 in total

1.  Cytoplasmic expression of EGFP in dendritic cells transfected with in vitro transcribed mRNA or cellular total RNA extracted from EGFP expressing leukemia cells.

Authors:  Masuhiro Takahashi; Miwako Narita; Flavio Ayres; Naoko Satoh; Takashi Abe; Toshio Yanao; Tatsuo Furukawa; Ken Toba; Takeshi Hirohashi; Yoshifusa Aizawa
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Authors:  Ozcan Met; Jens Eriksen; Inge Marie Svane
Journal:  Mol Biotechnol       Date:  2008-06-10       Impact factor: 2.695

3.  A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.

Authors:  Yongjun Wang; Shengyu Wang; Yuan Ding; Yanhua Ye; Yingyi Xu; Huixiang He; Qiaozhen Li; Yanjun Mi; Chunhua Guo; Zhicai Lin; Tao Liu; Yaya Zhang; Yuqiang Chen; Jianghua Yan
Journal:  Clin Vaccine Immunol       Date:  2013-07-24

Review 4.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01

5.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

Review 6.  Cancer immunotherapy using RNA-loaded dendritic cells.

Authors:  P Ponsaerts; V F I Van Tendeloo; Z N Berneman
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

7.  Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

Authors:  Jens Dannull; N Rebecca Haley; Gary Archer; Smita Nair; David Boczkowski; Mark Harper; Nicole De Rosa; Nancy Pickett; Paul J Mosca; James Burchette; Maria A Selim; Duane A Mitchell; John Sampson; Douglas S Tyler; Scott K Pruitt
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

8.  Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells.

Authors:  Matthew F Kalady; Mark W Onaitis; Sirisha Emani; Zeinab Abdul-Wahab; Scott K Pruitt; Douglas S Tyler
Journal:  J Gastrointest Surg       Date:  2004-02       Impact factor: 3.452

9.  Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.

Authors:  Dae-Hee Sohn; Hyun-Jung Sohn; Hyun-Joo Lee; Seon-Duk Lee; Sueon Kim; Seung-Joo Hyun; Hyun-Il Cho; Seok-Goo Cho; Suk-Kyeong Lee; Tai-Gyu Kim
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

10.  Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.

Authors:  Jacoba G Slagter-Jäger; Alexa Raney; Whitney E Lewis; Mark A Debenedette; Charles A Nicolette; Irina Y Tcherepanova
Journal:  Mol Ther Nucleic Acids       Date:  2013-05-07       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.